News
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic ...
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...
Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...
India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.
The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...
Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...
Referrals to an obesity clinic almost doubled after a novel educational intervention addressed negative attitudes and suboptimal practice patterns.
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
17d
Zacks.com on MSNWill AbbVie's Acquisition Spree Aid Pipeline Growth?The acquisition will also add Capstan’s proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, ...
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results